|
Study | Method of delivery | Patients treated/control | Placebo/control | Cell type cell/number or dose | Time of cell delivery (days after MI) | Results |
|
Strauer et al., 2002 [114] (Germany) | IC | 20/10 | Case controlled | BM-MNC 9–28 × 106 | 7 | Improved contractility and reduced infarct size at 6 months |
|
TOPCARE-AMI, Assmus et al. 2002 [117], Schächinger 2004 [118] (Germany) | IC | 30/29 | Control Nonrandomized open-labeled | BM-MNC 2.4 × 108 CPC 1.3 × 107 | 3 to 7 | Improved LVFE and reduced infract size at 4–12 months |
|
BOOST, Wollert et al. 2004 [119], | IC | 30/30 | Control | BM-MNC 24 × 109 | 6 | Improved EF at 6 months, increased regional contractility, |
Meyer et al. 2006 [125] (Germany) | | | | | | no difference at 18 months |
|
REPAIR-AMI, Schächinger et al. 2006 [123] (Germany) | IC | 102/102 | Placebo | BM-MNC 2.4 × 108 | 4 | Improved EF and reduced infarct size at 4 months |
|
Fernandez et al. 2004 [120] | IC | 20/13 | Control | BM-MNC 11–90 × 106 | 10–15 | Significant functional improvement and reduced infarct size |
|
Janssens et al., 2005 [122] (Belgium) | IC | 33/34 | Placebo | BM-MNC 3.0 × 108 cells | 1 | Decrease scar size but no improvement in LVEF at 4 months |
|
ASTAMI, lunde et al. 2006 [124] (Norway) | IC | 50/50 | Control Randomized + placebo controlled | BM-MNC 8.7 × 107 | 5 to 8 | No difference at 6 months |
|
Shah et al. 2007 [121, 126] (India) | IC | 20/10 | Control Open-label nonrandomized | BM-MNC 13.4 × 107 | 6 to 8 | Improved LV function at 6 months and sustained at 24 months |
|
Chen et al. 2004 [127] (China) | IC | 34/35 | Placebo Controlled | MCSs 48–68 × 1010 | 18 | Inc LVEF, Inc regional contractility, increase viability of infarct zone/wall after 3 and 6 months |
|
Hare et al. 2009 [129] (USA) | IV | 39/21 | Double-blind placebo controlled | MSCs 0.5, 1.6, 5 million cells/kg | 1, 2, 3, 6 months followup | Improved LVEF and reverse modeling |
|